Tinguely D, Jonzier M, Schöpf J, Koeb L, Baumann P
Arzneimittelforschung. 1985;35(2):536-8.
In a comprehensive study on the fate of amitriptyline (At, Laroxyl) in depressive patients, it was investigated whether their compliance could be controlled in analysing the concentration of riboflavin (vitamin B2) in urine. Therefore, they were medicated for 3 weeks with special tablets (Ro 4-1575/063) containing 150 mg At and 15 mg riboflavin. Different modalities or urine samplings were designed in order to establish the optimal conditions for testing compliance. Riboflavin, creatinine, At and nortriptyline were measured in urine, the tricyclic drugs also in plasma. The results show that compliance could be tested in analysing urine before and 4 h after the intake of the drug. However, this design was associated with a considerable subjective constraint for the patient.
在一项关于抑郁症患者体内阿米替林(阿密曲替林,Laroxyl)代谢情况的全面研究中,研究人员通过分析尿液中核黄素(维生素B2)的浓度来探究是否可以控制患者的服药依从性。为此,研究人员让患者服用了3周的特殊片剂(Ro 4-1575/063),该片剂含有150毫克阿密曲替林和15毫克核黄素。研究人员设计了不同的尿液采样方式,以确定检测服药依从性的最佳条件。研究人员检测了尿液中的核黄素、肌酐、阿密曲替林和去甲替林,同时也检测了血浆中的三环类药物。结果表明,可以通过分析服药前和服药后4小时的尿液来检测服药依从性。然而,这种设计给患者带来了相当大的主观限制。